Anna Alisi

List of Publications by Citations

228 papers	7,592 citations	50 h-index	77 g-index
266 ext. papers	9,203 ext. citations	5.5 avg, IF	6 L-index

#	Paper	IF	Citations
228	Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach. *Hepatology*, **2017**, 65, 451-464	11.2	354
227	Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. *Hepatology*, **2015**, 61, 506-14	11.2	311
226	Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. *Alimentary Pharmacology and Therapeutics*, **2014**, 39, 1276-85	6.1	269
225	I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. *Hepatology*, **2010**, 52, 1274-80	11.2	200
224	Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. *Archives of Disease in Childhood*, **2011**, 96, 350-3	2.2	195
223	Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease. *Laboratory Investigation*, **2011**, 91, 283-93	5.9	161
222	A 360-degree overview of paediatric NAFLD: recent insights. *Journal of Hepatology*, **2013**, 58, 1218-29	13.4	120
221	Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity. *Digestive and Liver Disease*, **2014**, 46, 556-60	3.3	115
220	Complications, morbidity and mortality of nonalcoholic fatty liver disease. *Metabolism: Clinical and Experimental*, **2020**, 111S, 154170	12.7	113
219	Antioxidant effects of natural bioactive compounds. *Current Pharmaceutical Design*, **2009**, 15, 3063-73	3.3	110
218	Hepatic progenitor cells activation, fibrosis, and adipokines production in pediatric nonalcoholic fatty liver disease. *Hepatology*, **2012**, 56, 2142-53	11.2	108
217	Pediatric nonalcoholic fatty liver disease in 2009. *Journal of Pediatrics*, **2009**, 155, 469-74	3.6	106
216	NAFLD in children: new genes, new diagnostic modalities and new drugs. *Nature Reviews Gastroenterology and Hepatology*, **2019**, 16, 517-530	24.2	105
215	Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. *Journal of Pediatric Gastroenterology and Nutrition*, **2010**, 50, 645-9	2.8	105
214	Low birth weight and catch-up-growth associated with metabolic syndrome: a ten year systematic review. *Pediatric Endocrinology Reviews*, **2008**, 6, 241-7	1.1	105
213	Lipid-induced hepatocyte-derived extracellular vesicles regulate hepatic stellate cell via microRNAs targeting PPAR-□*Cellular and Molecular Gastroenterology and Hepatology*, **2015**, 1, 646-663.e4	7.9	104
212	The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with non-alcoholic fatty liver disease. *BMC Medicine*, **2009**, 7, 21	11.4	98

211	Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study. *Clinical Therapeutics*, **2008**, 30, 1168-76	3.5	97
210	Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents. *Journal of Hepatology*, **2017**, 66, 1031-1036	13.4	94
209	Role of docosahexaenoic acid treatment in improving liver histology in pediatric nonalcoholic fatty liver disease. *PLoS ONE*, **2014**, 9, e88005	3.7	94
208	Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children. *Nutrition, Metabolism and Cardiovascular Diseases*, **2013**, 23, 1066-70	4.5	93
207	The Role of Tissue Macrophage-Mediated Inflammation on NAFLD Pathogenesis and Its Clinical Implications. *Mediators of Inflammation*, **2017**, 2017, 8162421	4.3	85
206	Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology*, **2016**, 150, 1798-810	13.3	84
205	Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children. *American Journal of Gastroenterology*, **2013**, 108, 1526-31	0.7	83
204	Nonalcoholic fatty liver disease: a challenge for pediatricians. *JAMA Pediatrics*, **2015**, 169, 170-6	8.3	82
203	Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach. *Nature Reviews Gastroenterology and Hepatology*, **2012**, 9, 152-61	24.2	79
202	LPS-induced TNF-□factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease. *Oncotarget*, **2015**, 6, 41434-52	3.3	78
201	Non-alcoholic fatty liver disease and metabolic syndrome in adolescents: pathogenetic role of genetic background and intrauterine environment. *Annals of Medicine*, **2012**, 44, 29-40	1.5	78
200	Vitamin D levels and liver histological alterations in children with nonalcoholic fatty liver disease. *European Journal of Endocrinology*, **2014**, 170, 547-53	6.5	73
199	The Benefit of Sleeve Gastrectomy in Obese Adolescents on Nonalcoholic Steatohepatitis and Hepatic Fibrosis. *Journal of Pediatrics*, **2017**, 180, 31-37.e2	3.6	73
198	The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage. *Hepatology*, **2016**, 63, 787-98	11.2	70
197	Multidrug resistance and cancer stem cells in neuroblastoma and hepatoblastoma. *International Journal of Molecular Sciences*, **2013**, 14, 24706-25	6.3	69
196	Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease. *PLoS ONE*, **2013**, 8, e67160	3.7	69
195	Combined paediatric NAFLD fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease. *Liver International*, **2013**, 33, 79-85	7.9	68
194	Oxidative stress parameters in paediatric non-alcoholic fatty liver disease. *International Journal of Molecular Medicine*, **2010**, 26, 471-6	4.4	67

193	Development and validation of a new histological score for pediatric non-alcoholic fatty liver disease. *Journal of Hepatology*, **2012**, 57, 1312-8	13.4	60
192	Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies. *Digestive and Liver Disease*, **2013**, 45, 543-51	3.3	60
191	A protective effect of breastfeeding on the progression of non-alcoholic fatty liver disease. *Archives of Disease in Childhood*, **2009**, 94, 801-5	2.2	60
190	Nonalcoholic fatty pancreas disease and Nonalcoholic fatty liver disease: more than ectopic fat. *Clinical Endocrinology*, **2015**, 83, 656-62	3.4	59
189	Plasma levels of homocysteine and cysteine increased in pediatric NAFLD and strongly correlated with severity of liver damage. *International Journal of Molecular Sciences*, **2014**, 15, 21202-14	6.3	59
188	A 4-polymorphism risk score predicts steatohepatitis in children with nonalcoholic fatty liver disease. *Journal of Pediatric Gastroenterology and Nutrition*, **2014**, 58, 632-6	2.8	58
187	Retinol-binding protein 4: a promising circulating marker of liver damage in pediatric nonalcoholic fatty liver disease. *Clinical Gastroenterology and Hepatology*, **2009**, 7, 575-9	6.9	57
186	Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial. *PLoS ONE*, **2016**, 11, e0168216	3.7	56
185	Bifidobacteria and lactobacilli in the gut microbiome of children with non-alcoholic fatty liver disease: which strains act as health players?. *Archives of Medical Science*, **2018**, 14, 81-87	2.9	55
184	Physical and functional interaction between HCV core protein and the different p73 isoforms. *Oncogene*, **2003**, 22, 2573-80	9.2	55
183	Intrauterine growth retardation and nonalcoholic Fatty liver disease in children. *International Journal of Endocrinology*, **2011**, 2011, 269853	2.7	54
182	Severity of liver injury and atherogenic lipid profile in children with nonalcoholic fatty liver disease. *Pediatric Research*, **2010**, 67, 665-70	3.2	52
181	Hyaluronic acid predicts hepatic fibrosis in children with nonalcoholic fatty liver disease. *Translational Research*, **2010**, 156, 229-34	11	50
180	Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. *Journal of Hepatology*, **2021**, 74, 775-782	13.4	50
179	The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-alcoholic fatty liver disease. *Journal of Medicinal Food*, **2013**, 16, 957-60	2.8	49
178	Markers of activated inflammatory cells correlate with severity of liver damage in children with nonalcoholic fatty liver disease. *International Journal of Molecular Medicine*, **2012**, 30, 49-56	4.4	46
177	LPIN1 rs13412852 polymorphism in pediatric nonalcoholic fatty liver disease. *Journal of Pediatric Gastroenterology and Nutrition*, **2012**, 54, 588-93	2.8	46
176	Portal inflammation is independently associated with fibrosis and metabolic syndrome in pediatric nonalcoholic fatty liver disease. *Hepatology*, **2016**, 63, 745-53	11.2	45

175	Focal Adhesion Kinase: Insight into Molecular Roles and Functions in Hepatocellular Carcinoma. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	44
174	Urinary (1)H-NMR-based metabolic profiling of children with NAFLD undergoing VSL#3 treatment. *International Journal of Obesity*, **2015**, 39, 1118-25	5.5	43
173	Risk of severe liver disease in NAFLD with normal ALT levels: a pediatric report. *Hepatology*, **2008**, 48, 2087-8; author reply 2088	11.2	41
172	Macrophage Activation in Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) Correlates with Hepatic Progenitor Cell Response via Wnt3a Pathway. *PLoS ONE*, **2016**, 11, e0157246	3.7	41
171	MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease. *World Journal of Gastroenterology*, **2014**, 20, 15079-86	5.6	40
170	Emodin prevents intrahepatic fat accumulation, inflammation and redox status imbalance during diet-induced hepatosteatosis in rats. *International Journal of Molecular Sciences*, **2012**, 13, 2276-89	6.3	40
169	EZH2 down-regulation exacerbates lipid accumulation and inflammation in in vitro and in vivo NAFLD. *International Journal of Molecular Sciences*, **2013**, 14, 24154-68	6.3	39
168	Influence of dietary pattern, physical activity, and I148M PNPLA3 on steatosis severity in at-risk adolescents. *Genes and Nutrition*, **2014**, 9, 392	4.3	38
167	Role of p38 MAPK and RNA-dependent protein kinase (PKR) in hepatitis C virus core-dependent nuclear delocalization of cyclin B1. *Journal of Biological Chemistry*, **2006**, 281, 10983-9	5.4	38
166	Elevated serum ALT in children presenting to the emergency unit: Relationship with NAFLD. *Digestive and Liver Disease*, **2009**, 41, 749-52	3.3	37
165	Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2. *Cell Death and Differentiation*, **2017**, 24, 889-902	12.7	36
164	Causative role of gut microbiota in non-alcoholic fatty liver disease pathogenesis. *Frontiers in Cellular and Infection Microbiology*, **2012**, 2, 132	5.9	36
163	Thyroid hormones regulate DNA-synthesis and cell-cycle proteins by activation of PKCalpha and p42/44 MAPK in chick embryo hepatocytes. *Journal of Cellular Physiology*, **2004**, 201, 259-65	7	36
162	Non-alcoholic fatty liver disease and hepatocellular carcinoma in a 7-year-old obese boy: coincidence or comorbidity?. *Pediatric Obesity*, **2014**, 9, e99-e102	4.6	35
161	Altered gut-liver axis and hepatic adiponectin expression in OSAS: novel mediators of liver injury in paediatric non-alcoholic fatty liver. *Thorax*, **2015**, 70, 769-81	7.3	34
160	Cannabinoid receptor type 2 functional variant influences liver damage in children with non-alcoholic fatty liver disease. *PLoS ONE*, **2012**, 7, e42259	3.7	34
159	Efficacy of docosahexaenoic acid-choline-vitamin E in paediatric NASH: a randomized controlled clinical trial. *Applied Physiology, Nutrition and Metabolism*, **2017**, 42, 948-954	3	33
158	Plasma cathepsin D levels: a novel tool to predict pediatric hepatic inflammation. *American Journal of Gastroenterology*, **2015**, 110, 462-70	0.7	33

157	Nonalcoholic fatty liver in children and adolescents: an overview. *Journal of Adolescent Health*, **2012**, 51, 305-12	5.8	33
156	Thyroid status affects rat liver regeneration after partial hepatectomy by regulating cell cycle and apoptosis. *Cellular Physiology and Biochemistry*, **2005**, 15, 69-76	3.9	33
155	Serum Bile Acid Levels in Children With Nonalcoholic Fatty Liver Disease. *Journal of Pediatric Gastroenterology and Nutrition*, **2015**, 61, 85-90	2.8	31
154	ADAR enzyme and miRNA story: a nucleotide that can make the difference. *International Journal of Molecular Sciences*, **2013**, 14, 22796-816	6.3	31
153	Transient elastography for assessment of fibrosis in paediatric liver disease. *Pediatric Radiology*, **2011**, 41, 1232-8	2.8	30
152	Non-alcoholic fatty liver disease in children now: lifestyle changes and pharmacologic treatments. *Nutrition*, **2012**, 28, 722-6	4.8	29
151	Association between type two diabetes and non-alcoholic fatty liver disease in youth. *Annals of Hepatology*, **2009**, 8, S44-S50	3.1	29
150	Nonalcoholic fatty liver disease in children. *Current Opinion in Clinical Nutrition and Metabolic Care*, **2010**, 13, 397-402	3.8	29
149	Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD. *Critical Reviews in Clinical Laboratory Sciences*, **2016**, 53, 106-20	9.4	28
148	OSAS-related inflammatory mechanisms of liver injury in nonalcoholic fatty liver disease. *Mediators of Inflammation*, **2015**, 2015, 815721	4.3	28
147	Non-alcoholic fatty liver and metabolic syndrome in children: a vicious circle. *Hormone Research in Paediatrics*, **2014**, 82, 283-9	3.3	28
146	Levels of serum ceruloplasmin associate with pediatric nonalcoholic fatty liver disease. *Journal of Pediatric Gastroenterology and Nutrition*, **2013**, 56, 370-5	2.8	28
145	Early interplay of intra-hepatic iron and insulin resistance in children with non-alcoholic fatty liver disease. *Journal of Hepatology*, **2011**, 55, 647-653	13.4	27
144	Nutritional and lipidomics biomarkers of docosahexaenoic acid-based multivitamin therapy in pediatric NASH. *Scientific Reports*, **2019**, 9, 2045	4.9	27
143	Klotho gene variation is associated with liver damage in children with NAFLD. *Journal of Hepatology*, **2020**, 72, 411-419	13.4	27
142	Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. *The Lancet Gastroenterology and Hepatology*, **2021**, 6, 864-873	18.8	27
141	Insulin-like growth factor-I and -II levels are associated with the progression of nonalcoholic fatty liver disease in obese children. *Journal of Pediatrics*, **2014**, 165, 92-8	3.6	26
140	Drug Transporters and Multiple Drug Resistance in Pediatric Solid Tumors. *Current Drug Metabolism*, **2016**, 17, 308-16	3.5	26

139	Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD. *Liver International*, **2018**, 38, 342-349	7.9	24
138	Toll-like receptor-mediated signaling cascade as a regulator of the inflammation network during alcoholic liver disease. *World Journal of Gastroenterology*, **2014**, 20, 16443-51	5.6	24
137	rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis. *Journal of Hepatology*, **2021**, 74, 20-30	13.4	24
136	Relationship Between PNPLA3 rs738409 Polymorphism and Decreased Kidney Function in Children With NAFLD. *Hepatology*, **2019**, 70, 142-153	11.2	23
135	Low Birthweight Increases the Likelihood of Severe Steatosis in Pediatric Non-Alcoholic Fatty Liver Disease. *American Journal of Gastroenterology*, **2017**, 112, 1277-1286	0.7	22
134	Liver fibrosis and therapeutic strategies: the goal for improving metabolism. *Current Drug Targets*, **2009**, 10, 505-12	3	22
133	The G-Quadruplex/Helicase World as a Potential Antiviral Approach Against COVID-19. *Drugs*, **2020**, 80, 941-946	12.1	22
132	Macrophages and fibrosis in adipose tissue are linked to liver damage and metabolic risk in obese children. *Obesity*, **2014**, 22, 1512-9	8	21
131	Meta-omic platforms to assist in the understanding of NAFLD gut microbiota alterations: tools and applications. *International Journal of Molecular Sciences*, **2014**, 15, 684-711	6.3	21
130	PKR is a novel functional direct player that coordinates skeletal muscle differentiation via p38MAPK/AKT pathways. *Cellular Signalling*, **2008**, 20, 534-42	4.9	21
129	A review of the pathogenic and therapeutic role of nutrition in pediatric nonalcoholic fatty liver disease. *Nutrition Research*, **2018**, 58, 1-16	4	21
128	I148M PNPLA3 variant and progressive liver disease: A new paradigm in hepatology. *Hepatology*, **2012**, 56, 791	11.2	20
127	Novel Tween 20 derivatives enable the formation of efficient pH-sensitive drug delivery vehicles for human hepatoblastoma. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 3021-5	2.9	20
126	Thr 446 phosphorylation of PKR by HCV core protein deregulates G2/M phase in HCC cells. *Journal of Cellular Physiology*, **2005**, 205, 25-31	7	20
125	Activation of an endothelial Notch1-Jagged1 circuit induces VCAM1 expression, an effect amplified by interleukin-1 *Oncotarget*, **2015**, 6, 43216-29	3.3	20
124	Plasma high mobility group box 1 protein reflects fibrosis in pediatric nonalcoholic fatty liver disease. *Expert Review of Molecular Diagnostics*, **2014**, 14, 763-71	3.8	19
123	Liver fibrosis in paediatric liver diseases. *Baillieres Best Practice and Research in Clinical Gastroenterology*, **2011**, 25, 259-68	2.5	19
122	Focal adhesion kinase (FAK) mediates the induction of pro-oncogenic and fibrogenic phenotypes in hepatitis C virus (HCV)-infected cells. *PLoS ONE*, **2012**, 7, e44147	3.7	19

121	Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease. *Journal of Hepatology*, **2019**, 71, 802-810	13.4	18
120	Reduced lysosomal acid lipase activity - A potential role in the pathogenesis of non alcoholic fatty liver disease in pediatric patients. *Digestive and Liver Disease*, **2016**, 48, 909-13	3.3	18
119	Association between type two diabetes and non-alcoholic fatty liver disease in youth. *Annals of Hepatology*, **2009**, 8 Suppl 1, S44-50	3.1	18
118	Circulating Soluble Fas and Fas Ligand Levels Are Elevated in Children with Nonalcoholic Steatohepatitis. *Digestive Diseases and Sciences*, **2015**, 60, 2353-9	4	17
117	Recent advances in understanding the role of adipocytokines during non-alcoholic fatty liver disease pathogenesis and their link with hepatokines. *Expert Review of Gastroenterology and Hepatology*, **2016**, 10, 393-403	4.2	17
116	Paediatric nonalcoholic fatty liver disease. *Current Opinion in Gastroenterology*, **2013**, 29, 279-84	3	17
115	Autoimmune hepatitis type 2 following anti-papillomavirus vaccination in a 11-year-old girl. *Vaccine* , **2011**, 29, 4654-6	4.1	17
114	Diagnostic power of fibroscan in predicting liver fibrosis in nonalcoholic fatty liver disease. *Hepatology*, **2009**, 50, 2048-9; author reply 2049-50	11.2	17
113	Involvement of PI3K in HCV-related lymphoproliferative disorders. *Journal of Cellular Physiology*, **2008**, 214, 396-404	7	17
112	The Antioxidant Effects of Hydroxytyrosol and Vitamin E on Pediatric Nonalcoholic Fatty Liver Disease, in a Clinical Trial: A New Treatment?. *Antioxidants and Redox Signaling*, **2019**, 31, 127-133	8.4	17
111	Laparoscopic Sleeve Gastrectomy Improves Nonalcoholic Fatty Liver Disease-Related Liver Damage in Adolescents by Reshaping Cellular Interactions and Hepatic Adipocytokine Production. *Journal of Pediatrics*, **2018**, 194, 100-108.e3	3.6	17
110	Microarray technology: a promising tool in nutrigenomics. *Critical Reviews in Food Science and Nutrition*, **2010**, 50, 693-8	11.5	16
109	Glutathionylation of p65NF-kappaB correlates with proliferating/apoptotic hepatoma cells exposed to pro- and anti-oxidants. *International Journal of Molecular Medicine*, **2009**, 24, 319-26	4.4	16
108	Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name. *Metabolism: Clinical and Experimental*, **2020**, 113, 154413	12.7	16
107	Engineered Escherichia coli as new source of flavonoids and terpenoids. *Food Research International*, **2013**, 54, 1084-1095	7	15
106	Viral hepatitis B: established and emerging therapies. *Current Medicinal Chemistry*, **2008**, 15, 930-9	4.3	15
105	AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF). *Digestive and Liver Disease*, **2016**, 48, 860-8	3.3	14
104	The exposure to uteroplacental insufficiency is associated with activation of unfolded protein response in postnatal life. *PLoS ONE*, **2018**, 13, e0198490	3.7	14

103	Plasma N-terminal propeptide of type III procollagen accurately predicts liver fibrosis severity in children with non-alcoholic fatty liver disease. *Liver International*, **2019**, 39, 2317-2329	7.9	14
102	Effect of fructose and 3,5-diiodothyronine (3,5-T(2)) on lipid accumulation and insulin signalling in non-alcoholic fatty liver disease (NAFLD)-like rat primary hepatocytes. *Hormone and Metabolic Research*, **2014**, 46, 333-40	3.1	14
101	Elevated Hemoglobin Level Is Associated With Advanced Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease. *Journal of Pediatric Gastroenterology and Nutrition*, **2017**, 65, 150-155	2.8	13
100	Pediatric liver diseases: current challenges and future perspectives. *Expert Review of Gastroenterology and Hepatology*, **2016**, 10, 255-65	4.2	13
99	Redox homeostasis and posttranslational modifications/activity of phosphatase and tensin homolog in hepatocytes from rats with diet-induced hepatosteatosis. *Journal of Nutritional Biochemistry*, **2012**, 23, 169-78	6.3	13
98	Nonalcoholic Fatty Liver Disease in Italian Children with Down Syndrome: Prevalence and Correlation with Obesity-Related Features. *Journal of Pediatrics*, **2017**, 189, 92-97.e1	3.6	13
97	Arterial Stiffness, Thickness and Association to Suitable Novel Markers of Risk at the Origin of Cardiovascular Disease in Obese Children. *International Journal of Medical Sciences*, **2017**, 14, 711-720	3.7	13
96	Antioxidant activity of Hydroxytyrosol and Vitamin E reduces systemic inflammation in children with paediatric NAFLD. *Digestive and Liver Disease*, **2021**, 53, 1154-1158	3.3	13
95	Fructose at the center of necroinflammation and fibrosis in nonalcoholic steatohepatitis. *Hepatology*, **2011**, 53, 372-3	11.2	12
94	Expert opinion on current therapies for nonalcoholic fatty liver disease. *Expert Opinion on Pharmacotherapy*, **2011**, 12, 1901-11	4	12
93	Circulating miRNA profiling to identify biomarkers of dysmetabolism. *Biomarkers in Medicine*, **2012**, 6, 729-42	2.3	12
92	Hepatitis C virus core protein enhances B lymphocyte proliferation. *Digestive and Liver Disease*, **2007**, 39 Suppl 1, S72-5	3.3	12
91	Treatment with EGF increases the length of S-Phase after partial hepatectomy in rat, changing the activities of cdks. *Cellular Physiology and Biochemistry*, **2003**, 13, 239-48	3.9	12
90	Does Nox2 Overactivate in Children with Nonalcoholic Fatty Liver Disease?. *Antioxidants and Redox Signaling*, **2019**, 30, 1325-1330	8.4	11
89	Hepatitis C virus and alcohol: same mitotic targets but different signaling pathways. *Journal of Hepatology*, **2011**, 54, 956-63	13.4	11
88	PNPLA3 rs738409 Polymorphism Predicts Development and Severity of Hepatic Steatosis but Not Metabolic Syndrome in Celiac Disease. *Nutrients*, **2018**, 10,	6.7	11
87	The Number of Liver Galectin-3 Positive Cells Is Dually Correlated with NAFLD Severity in Children. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	9
86	Energy expenditure and insulin sensitivity evaluation in obese children affected by hepatosteatosis. *Pediatric Obesity*, **2012**, 7, e14-7	4.6	9

85	Relationship between portal chronic inflammation and disease severity in paediatric non-alcoholic fatty liver disease. *Digestive and Liver Disease*, **2011**, 43, 143-6	3.3	9
84	The Role of Genetic Predisposition, Programing During Fetal Life, Family Conditions, and Post-natal Diet in the Development of Pediatric Fatty Liver Disease. *Journal of Pediatrics*, **2019**, 211, 72-77.e4	3.6	8
83	Hepatitis C virus (HCV): an RNA virus with a pro-oncogenic potential. *Digestive and Liver Disease*, **2007**, 39 Suppl 1, S46-51	3.3	7
82	Enhancing the efficacy of hepatocellular carcinoma chemotherapeutics with natural anticancer agents. *Nutrition Reviews*, **2007**, 65, 550-3	6.4	7
81	Circulating histone signature of human lean metabolic-associated fatty liver disease (MAFLD). *Clinical Epigenetics*, **2020**, 12, 126	7.7	7
80	Early Glucose Derangement Detected by Continuous Glucose Monitoring and Progression of Liver Fibrosis in Nonalcoholic Fatty Liver Disease: An Independent Predictive Factor?. *Hormone Research in Paediatrics*, **2016**, 85, 29-34	3.3	6
79	High concentrations of H2O2 trigger hypertrophic cascade and phosphatase and tensin homologue (PTEN) glutathionylation in H9c2 cardiomyocytes. *Experimental and Molecular Pathology*, **2016**, 100, 199-206	4.4	6
78	In a pilot study, reduced fatty acid desaturase 1 function was associated with nonalcoholic fatty liver disease and response to treatment in children. *Pediatric Research*, **2018**, 84, 696-703	3.2	6
77	Current pharmacotherapy for treating pediatric nonalcoholic fatty liver disease. *Expert Opinion on Pharmacotherapy*, **2014**, 15, 2501-11	4	6
76	Commentary: FGF21 holds promises for treating obesity-related insulin resistance and hepatosteatosis. *Endocrinology*, **2014**, 155, 343-6	4.8	6
75	Toll-like receptor 4: a starting point for proinflammatory signals in fatty liver disease. *Hepatology*, **2010**, 51, 714-5	11.2	6
74	GDF11 induces mild hepatic fibrosis independent of metabolic health. *Aging*, **2020**, 12, 20024-20046	5.6	6
73	TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models. *Cellular and Molecular Gastroenterology and Hepatology*, **2021**,	7.9	6
72	The rs599839 A>G Variant Disentangles Cardiovascular Risk and Hepatocellular Carcinoma in NAFLD Patients. *Cancers*, **2021**, 13,	6.6	6
71	Maternal Intake of n-3 Polyunsaturated Fatty Acids During Pregnancy Is Associated With Differential Methylation Profiles in Cord Blood White Cells. *Frontiers in Genetics*, **2019**, 10, 1050	4.5	6
70	Macrophage Markers Are Poorly Associated With Liver Histology in Children With Nonalcoholic Fatty Liver Disease. *Journal of Pediatric Gastroenterology and Nutrition*, **2018**, 67, 635-642	2.8	6
69	Is there any link between dietary pattern and development of nonalcoholic fatty liver disease in adolescence? An expert review. *Expert Review of Gastroenterology and Hepatology*, **2013**, 7, 601-4	4.2	5
68	Psychosocial condition after liver transplantation in children: review of the literature from 2006 to 2008. *Transplantation Proceedings*, **2009**, 41, 3779-83	1.1	5

67	HCV-Related Transformation and New Therapeutic Strategies: An Update. *Current Cancer Therapy Reviews*, **2006**, 2, 41-56	0.4	5
66	Molecular genetics of NASH: the role of polymorphisms. *Journal of Hepatology*, **2007**, 47, 868-9; author reply 870-1	13.4	5
65	HDL cholesterol protects from liver injury in mice with intestinal specific LXR activation. *Liver International*, **2020**, 40, 3127-3139	7.9	5
64	The Contribution of the Adipose Tissue-Liver Axis in Pediatric Patients with Nonalcoholic Fatty Liver Disease after Laparoscopic Sleeve Gastrectomy. *Journal of Pediatrics*, **2020**, 216, 117-127.e2	3.6	5
63	Metabolic-associated fatty liver disease (MAFLD) in coeliac disease. *Liver International*, **2021**, 41, 788-798	7.9	5
62	Association of Bright Liver With the PNPLA3 I148M Gene Variant in 1-Year-Old Toddlers. *Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 2163-2170	5.6	4
61	Arginase 1: a potential marker of a common pattern of liver steatosis in HCV and NAFLD children. *Journal of Hepatology*, **2015**, 62, 1207-8	13.4	4
60	Serum Fetuin-A levels in obese children with biopsy proven nonalcoholic fatty liver disease. *Nutrition, Metabolism and Cardiovascular Diseases*, **2018**, 28, 71-76	4.5	4
59	Hedgehog/hyaluronic acid interaction network in nonalcoholic fatty liver disease, fibrosis, and hepatocellular carcinoma. *Hepatology*, **2012**, 56, 1589	11.2	4
58	Activation of the endotoxin/toll-like receptor 4 pathway: the way to go from nonalcoholic steatohepatitis up to hepatocellular carcinoma. *Hepatology*, **2011**, 53, 1069	11.2	4
57	Human hepatic stellate cells are liver-resident antigen-presenting cells. *Hepatology*, **2011**, 54, 1107	11.2	4
56	Expression of multidrug resistance-associated proteins in paediatric soft tissue sarcomas before and after chemotherapy. *International Journal of Oncology*, **2012**, 41, 117-24	4.4	4
55	Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2020**, 1865, 158765	5	4
54	A Lipidomic Signature Complements Stemness Features Acquisition in Liver Cancer Cells. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	4
53	Epigenetic remodelling in human hepatocellular carcinoma.. *Journal of Experimental and Clinical Cancer Research*, **2022**, 41, 107	12.8	4
52	Thyroid Hormones and their Metabolites: Biological Roles and Association with Non-Alcoholic Fatty Liver Disease. *Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry*, **2015**, 15, 43-59		3
51	Profiling microRNA expression: a snapshot of nonalcoholic steatohepatitis and a recording of its pathogenesis. *Hepatology*, **2009**, 49, 706-7	11.2	3
50	Portal inflammation as index of steatohepatitis in children with nonalcoholic fatty liver disease. *Hepatology*, **2009**, 50, 659	11.2	3

49	Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects. *Journal of Experimental and Clinical Cancer Research*, **2021**, 40, 364	12.8	3
48	Noninvasive diagnostic tools for pediatric NAFLD: where are we now?. *Expert Review of Gastroenterology and Hepatology*, **2020**, 14, 1035-1046	4.2	3
47	Focal Adhesion Kinase (FAK) Over-Expression and Prognostic Implication in Pediatric Hepatocellular Carcinoma. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	3
46	TM6SF2/PNPLA3/MBOAT7 loss-of-function genetic variants impact on NAFLD development and progression both in patients and in in vitro models. *Digestive and Liver Disease*, **2020**, 52, e7-e8	3.3	2
45	The anti-inflammatory effects of hydroxytyrosol and vitamin e on paediatric NAFLD. *Digestive and Liver Disease*, **2020**, 52, e42-e43	3.3	2
44	Expression of insulin-like growth factor I and its receptor in the liver of children with biopsy-proven NAFLD. *PLoS ONE*, **2018**, 13, e0201566	3.7	2
43	Letter to the Editor: Focal Adhesion Kinase/Catenin Network May Act as a Regulator of Hepatocellular Carcinoma Epigenetics. *Hepatology*, **2019**, 70, 1494-1495	11.2	2
42	Metabolic syndrome and alcohol abuse: a potential hepatocarcinogenic mix in adolescents. *Clinical Gastroenterology and Hepatology*, **2012**, 10, 204; author reply 204-5	6.9	2
41	Dual role of survivin in non-alcoholic fatty liver disease. *Liver International*, **2011**, 31, 1416-7; author reply 1417	7.9	2
40	The wide spectrum of hepatic iron overload. *Hepatology*, **2011**, 53, 1057-8; author reply 1058-9	11.2	2
39	Current treatment for nonalcoholic fatty liver disease. *Expert Opinion on Pharmacotherapy*, **2011**, 12, 2141-2; author reply 2142	4	2
38	Transient elastography and serum biomarkers: two-step screening methods for liver fibrosis in non-alcoholic fatty liver disease before liver biopsy. *Expert Opinion on Medical Diagnostics*, **2012**, 6, 377-80		2
37	Bioinformatics as tool to identify gene/protein-pathways associated with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. *Hepatology*, **2007**, 46, 1306; author reply 1306-7	11.2	2
36	Molecular pathogenesis of nonalcoholic steatohepatitis: today and tomorrow. *American Journal of Pathology*, **2007**, 171, 712-3; author reply 713	5.8	2
35	Circulating microRNAs as novel non-invasive biomarkers of paediatric celiac disease and adherence to gluten-free diet.. *EBioMedicine*, **2022**, 76, 103851	8.8	2
34	The G-quadruplex/helicase world as a potential antiviral approach against COVID-19		2
33	Plasma lipidomics identifies a signature of NAFLD in children that couples with cardiometabolic outcomes in adults		2
32	The pharmacological treatment of nonalcoholic fatty liver disease in children. *Expert Review of Clinical Pharmacology*, **2020**, 13, 1219-1227	3.8	2

31	Commentary: The histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity. *Frontiers in Genetics*, **2018**, 9, 443	4.5	2
30	Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17-beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms.. *Hepatology Communications*, **2022**,	6	2
29	NASH and the Cross-Talk Between the Gut and Liver. *Current Pediatrics Reports*, **2014**, 2, 211-217	0.7	1
28	Daclatasvir: a promising triple therapy for children with chronic hepatitis C. *Lancet Infectious Diseases, The*, **2013**, 13, 17-8	25.5	1
27	Targeting FGF19 binding to its receptor system: a novel therapeutic approach for hepatocellular carcinoma. *Hepatology*, **2015**, 62, 1324	11.2	1
26	Recent advances in biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis: the role of lipid analysis/profiling. *Clinical Lipidology*, **2011**, 6, 427-436		1
25	Supplementation of monounsaturated and polyunsaturated fatty acids in non-alcoholic fatty liver disease and metabolic syndrome. *Lipids*, **2011**, 46, 389-90	1.6	1
24	Metabolic syndrome and nonalcoholic steatohepatitis recurrence after liver transplantation in children. *Liver Transplantation*, **2011**, 17, 620-1	4.5	1
23	Hepatic stellate cell proliferation: a potential role of protein kinase R. *Hepatology*, **2011**, 54, 1484-5; author reply 1485-6	11.2	1
22	Hepatitis C virus and nonalcoholic Fatty liver disease: similar risk factors for necroinflammation, fibrosis, and cirrhosis. *Clinical Gastroenterology and Hepatology*, **2010**, 8, 97; author reply 97	6.9	1
21	Indirect markers of fibrosis in chronic liver diseases: Is aspartate transaminase-to-platelet ratio (APRI) a useful test?. *Hepatitis Monthly*, **2011**, 11, 558-9	1.8	1
20	Variants in MARC1 and HSD17B13 reduce severity of NAFLD in children, perturb phospholipid metabolism, and suppress fibrotic pathways		1
19	Fatty Liver Disease **2010**, 201-222		1
18	The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation. *EBioMedicine*, **2021**, 65, 103249	8.8	1
17	Pediatric Non-Alcoholic Fatty Liver Disease Is Affected by Genetic Variants Involved in Lifespan/Healthspan. *Journal of Pediatric Gastroenterology and Nutrition*, **2021**, 73, 161-168	2.8	1
16	Cytokine expression patterns in hospitalized children with Bordetella pertussis, Rhinovirus or co-infection. *Scientific Reports*, **2021**, 11, 10948	4.9	1
15	Changes in Total Homocysteine and Glutathione Levels After Laparoscopic Sleeve Gastrectomy in Children with Metabolic-Associated Fatty Liver Disease. *Obesity Surgery*, **2021**, 1	3.7	1
14	The Role of Phytosterols in Nonalcoholic Fatty Liver Disease. *Nutrients*, **2022**, 14, 2187	6.7	1

13	PNPLA3 gene polymorphism is associated with liver steatosis in children with Down syndrome. *Nutrition, Metabolism and Cardiovascular Diseases*, **2020**, 30, 1564-1572	4.5	0
12	Retinoids counteract insulin resistance and liver steatosis: what's the potential mechanism?. *Hepatology*, **2013**, 58, 1185	11.2	0
11	From pregnant women to infants: Non-alcoholic fatty liver disease is a poor inheritance. *Journal of Hepatology*, **2020**, 73, 1590-1592	13.4	0
10	Obesity and Nonalcoholic Fatty Liver Disease in Children **2019**, 209-222		0
9	Effect of treatment with polyunsaturated fatty acids on HCV- or diet-induced fatty liver. *Journal of Hepatology*, **2011**, 54, 1325-6; author reply 1326	13.4	
8	Role of Fatty Liver Disease in Childhood Obesity **2011**, 221-230		
7	Hepatitis C virus therapeutics: editing enzymes promising therapeutic targets?. *Hepatology*, **2011**, 54, 742; author reply 742-3	11.2	
6	Functions and therapeutic value of focal adhesion kinase signaling during hepatocellular carcinoma development and progression. *Hepatology*, **2010**, 51, 1092-3	11.2	
5	Natural approach against lipotoxic traffic in nonalcoholic fatty liver disease. *Hepatology*, **2010**, 52, 399	11.2	
4	The link between hepatosteatosis and cells of the immune system. *Hepatology*, **2010**, 51, 1472; author reply 1472-3	11.2	
3	Copper-catalyzed dicarbonyl stress in NAFLD mice: protective effects of Oleuropein treatment on liver damage.. *Nutrition and Metabolism*, **2022**, 19, 9	4.6	
2	Is obesity in childhood protective for breast cancer in young women?. *Translational Cancer Research* , **2019**, 8, 1012-1013	0.3	
1	Non-Invasive Diagnostic Test for Advanced Fibrosis in Adolescents With Non-Alcoholic Fatty Liver Disease.. *Frontiers in Pediatrics*, **2022**, 10, 885576	3.4	